ESC 365 - Options in thrombosis prevention and vascular health – What’s on the horizon?

HFA Premium Access

Options in thrombosis prevention and vascular health – What’s on the horizon?

Session: Management of co-morbidities in heart failure - Exploring new frontiers

Topic: Acute heart failure (other)

Speaker: Professor K. Fox (Edinburgh, GB)

Sponsored by Bayer AG

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Professor Keith Fox

University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)

45 presentations

1 follower

5 more presentations in this session

Introduction & remarks.

Speaker: Professor N. Danchin (Paris, FR)

Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).

Speaker: Professor M. Cowie (Cambridge, GB)

Broadening the evidence base for rivaroxaban in heart failure.

Speaker: Professor B. Greenberg (La Jolla, US)

Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?

Speaker: Doctor R. Mentz (Durham, US)

Q&A and closing remarks.

Speaker: Professor M. Cowie (Cambridge, GB)

Access the full session

Management of co-morbidities in heart failure - Exploring new frontiers

Speakers: Professor K. Fox, Professor N. Danchin, Professor M. Cowie, Professor B. Greenberg, Doctor R. Mentz...

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources